SUMMARY Background
Infliximab has been found to be efficacious in the treatment of fistulas in the setting of Crohn's disease, even though some patients do not benefit from therapy.
Aim
To assess the correlation between perianal fistula healing and trough levels of infliximab.
Methods
In this cross-sectional study, we identified patients with Crohn's disease who had perianal fistulas and were treated with infliximab for at least 24 weeks. We excluded patients who underwent a faecal diversion procedure or proctectomy. Predictive variables included demographics, disease phenotype, disease activity, infliximab levels, anti-infliximab antibodies. The primary outcome was fistula healing defined as the absence of drainage. The secondary outcome was complete fistula closure and mucosal healing.
Results 117 patients were included. Patients with fistula healing had significantly higher median serum infliximab levels when compared to those with active fistulas [15.8 vs. 4 .4 lg/mL, respectively (P < 0.0001)]. There was an incremental gain in fistula healing with higher infliximab levels. The AUC for the association between fistula healing and infliximab levels was 0.82 (P < 0.0001), while the AUC for the association of infliximab levels and fistula closure was 0.69 (P = 0.014). Patients with anti-infliximab antibodies had a lower chance of achieving fistula healing (OR: 0.04 [95%CI: 0.005-0.3], P < 0.001).
Conclusions
There is a significant association between serum infliximab levels and rates of fistula healing. Achieving infliximab levels ≥10.1 mcg/mL in patients with Crohn's disease and perianal fistulas may improve outcomes as part of a treat-to-target strategy.
BACKGROUND
Crohn's disease is a chronic and recurrent inflammatory bowel disease that can involve any area of the gastrointestinal tract, from the oral cavity to the anus. Patients can present with perianal manifestations including perianal skin tags, anorectal strictures, anal fissures, perianal fistulas and abscesses. Up to 20% of patients with Crohn's disease develop perianal fistulas and present with a variety of symptoms including perianal drainage, pain, abscess formation, dyspareunia, and faecal incontinence. 1 Perianal fistulas are morbid and associated with decreased quality of life. 2 Symptoms can vary from anal pain and purulent discharge to bleeding and incontinence. Therapies used in the treatment of perianal fistulas in the setting of Crohn's disease include antibiotics, azathioprine and mercaptopurine, ciclosporin, tacrolimus and anti-tumour necrosis factor (TNF) antibodies. 3 While evidence for most agents is limited to uncontrolled trials or post hoc analysis of studies for active Crohn's disease, two randomised, placebo-controlled trials have shown efficacy of infliximab in the treatment of fistulising disease (induction and maintenance). 4, 5 Unfortunately, a significant proportion of patients only partially respond to therapy and others do not respond at all. There is growing evidence showing that higher infliximab levels and the absence of anti-infliximab antibodies are associated with a higher rate of disease remission and mucosal healing. [6] [7] [8] [9] Moreover, the use of therapeutic drug monitoring in patient on infliximab has been associated with better outcomes. 10 Nevertheless, there is very limited data regarding the association between infliximab levels and perianal fistula healing in patients with Crohn's disease. The aim of this study was to assess the correlation between perianal fistula healing and serum trough levels of infliximab and antibodies to infliximab. We also sought to assess the association of infliximab levels and fistula closure.
MATERIALS AND METHODS

Study design and patient population
We designed a retrospective cross-sectional study approved by the Institutional were measured using a drug-tolerant commercially available homogeneous mobility shift assay as previously described.
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Outcomes
The primary outcome was fistula healing, defined as the absence of drainage, without a seton and as documented at the time of endoscopic exam (colonoscopy or sigmoidoscopy, Olympus America Inc., Central Valley, PA, USA). The assessment was done retrospectively based on colonoscopy reports and photographic documentation collected at the time of the procedure. Participating sites perform a systematic assessment of the perianal evaluation in patients with Crohn's disease during colonoscopies. This outcome was chosen based on previous clinical trials. 4, 5, 13 The secondary outcomes were fistula closure, defined as the absence of a skin opening and mucosal healing defined as the absence of ulcerations ≥5 mm in the colon and terminal ileum.
Statistical analysis
Descriptive statistics were used to examine the baseline characteristics of the cohorts. Continuous variables were compared using Student's t test or the Mann-Whitney U Test (for non-normally distributed variables). Normality of continuous variables was evaluated using the ShapiroWilk W test. The Chi-square test was used to evaluate distributions of categorical variables. Pearson's correlation (for parametric variables) and Spearman's rank correlation (for non-normally distributed variables) coefficients were used to evaluate the relationship between continuous variables. A multiple logistic regression model was built to identify those variables that were associated with the primary and secondary outcomes. Two-sided probabilities were considered, and a values of <0.05 were considered statistically significant.
RESULTS
Patient demographics
Out of 345 patients first screened, 117 patients with infliximab levels and colonoscopies were performed within 4 weeks of each other and had documented perianal exam were included [57 women (48.7%)]. Table 1 shows the baseline characteristics of the study population. Patients had been on infliximab for a median of 29 weeks (range of 24-168 weeks). Seventy-four patients had dose escalation (63.2%). Most patients had colonic involvement and stricturing phenotype (Table 1 ). The median infliximab trough level of the entire study group was 10 mcg/mL (IQR: 2.8 - No patients had known concomitant perianal abscesses at the index date (fistula assessment). There was a negative correlation between infliximab level and CRP levels (rho: À0.31, P < 0.001) and a positive correlation between infliximab level and serum albumin (rho: 0.48, P < 0.0001). Fistula healing Sixty-three patients (53.9%) achieved fistula healing. Those patients with fistula healing had significantly higher median infliximab level [15.8 mcg/mL (IQR: 9.9-27) and 4.4 mcg/mL (IQR: 0-9.8), P < 0.0001- Figure 1 ] and a lower rate of detectable antibodies to infliximab (1.6% vs. 29.6%), P < 0.0001 when compared to those without fistula healing (Table 2 ). There was a strong correlation between serum infliximab levels and fistula healing (ROC: 0.82, P < 0.0001 - Figure 2) . Patients on infliximab for ≥29 weeks (the median amount of time the study group was on the drug) did not have a higher rate of fistula healing when compared to those that had been on the drug for less than 29 weeks. When infliximab level were stratified by quartiles, there was a linear relationship between quartiles and fistula healing (Figure 3) . Patients with infliximab level in the third quartile (10.1-20.2 mcg/mL) had almost a three-fold chance of achieving fistula healing when compared to the first quartile (0-2.8 mcg/mL) [OR: 2.7 (95% CI: 1.1-6.7), P = 0.03] while those patients with infliximab level in the fourth quartile (20.3-50 mcg/mL) had an eight-fold chance of achieving fistula healing when compared to the first quartile [OR: 8.2 (95% CI: 2.6-25.6), P < 0.0001]. Conversely, those patients in the Table 2 . In the multivariate analysis, and when adjusting those variables that were found significant in the univariate analysis, only an infliximab level ≥10.1 mcg/mL maintained statistical significance [OR: 3.9 (95%CI: 1.34-11.8) P = 0.012].
Fistula closure
Thirty-six patients (31%) achieved fistula closure. Seven, 25, 42 and 48% of patients in the first, second, third and fourth quartile had fistula closure (Figure 3 ). Those patients with fistula closure had significantly higher infliximab levels, lower CRP levels, a higher rate of mucosal healing, and were more likely to be men (Table 3) . Furthermore, none of the patients with fistula closure had detectable antibodies to infliximab, while 16 (29.6%) of those with no fistula closure had antibodies to infliximab (P < 0.0001). When adjusting for those variables that were found significant in the univariate analysis, a infliximab levels ≥10.1 mcg/mL and male gender maintained statistical significance [OR: 2.9 (95%CI: 1.1-8.7) P = 0.036 and OR: 2.4 (95%CI: 1.02-5.8) P = 0.044].
Of those patients who did not achieve fistula closure, 27 (75%) had fistula healing. Median infliximab level (Figure 3 ).
Mucosal healing
Fifty-four of the 117 patients (46.1%) included in the study had mucosal healing (lack of colonic or small bowel ulcerations). Twenty-one, 47, 71 and 76% of patients in the first, second, third and fourth quartile had mucosal healing, respectively ( Figure 3 ). Those with mucosal healing had a higher infliximab levels, lower rate of antibodies to infliximab, had a lower rate of smoking and a higher proportion required infliximab dose escalation ( (Figure 4 ). However, unlike fistula healing (but similar to fistula closure), the absolute difference in mucosal healing rates between the third and fourth quartile rate was only 5%.
DISCUSSION
Perianal fistulas can be a devastating complication of Crohn's disease, and patients often require aggressive medical and surgical therapy. In this study, we found a significant association between serum infliximab levels and rates of fistula healing and fistula closure. We also found that the levels associated with fistula healing/closure were higher than those previously associated with mucosal healing. 7, 8 While rates of mucosal healing and fistula closure reached their peak in the third quartile (infliximab levels of 10.1-20.1 mcg/mL), the rate of Table 4 | Differences between patients with and without mucosal healing fistula healing increased by an absolute rate of 15% when comparing the third and fourth quartiles.
Previous studies have not examined the relationship between infliximab levels and fistula healing while on maintenance infliximab therapy. Often when patients experience fistula healing-even without complete closure, they have an improvement in quality of life. When patients do not achieve fistula healing, clinicians may be tempted to change therapy. Our data suggest that optimisation of anti-TNF may be beneficial. Indeed, we found that levels of infliximab ≥10 mcg/mL were best associated with fistula healing. Furthermore, a small number of patients achieved fistula healing at levels of ≥20 mcg/mL. While not all patients require those levels, we would suggest that patients who have not experienced fistula healing should be given a trial of infliximab at higher doses before considering the patient as a nonresponder.
Infliximab has been proven to be efficacious in the treatment of fistulising disease. Nevertheless, not all patients achieve remission. In a randomised controlled trial comparing infliximab and placebo for fistulas in Crohn's disease, Present et al. showed that 55% of the patients assigned to receive 5 mg of infliximab per kilogram had closure of all fistulas, as compared with 13% of the patients assigned to placebo (in two consecutive visits, 21 days apart). 4 While the difference between infliximab and placebo was significant, a large proportion of patients did not respond. Considering the results of our study, we could propose that measuring levels on these patients and optimising the drug dose may lead to improved efficacy. The association we found in this study may be explained by a higher TNF burden patients with penetrating Crohn's disease may have. A Spanish study found that patients receiving infliximab for fistulising Crohn's disease that did not respond to therapy had higher serum TNF levels when compared to those who did respond.
14 In a randomised controlled trial looking at infliximab as a maintenance agent in fistula healing, Sands et al. showed that even in those patients that did respond during the induction phase, 36% of patients had a complete absence of draining fistulas at week 54 (compared to 19% in placebo). 5 Interestingly, there was no difference in the rate of positive antibodies to infliximab between those that did and did not maintain remission. The role of therapeutic drug monitoring in this setting needs further studies. A recent study done looking into infliximab levels during induction for Crohn's disease found that higher levels at weeks 2, 6 and 14 were associated with the absence or improvement in fistula drainage. 15 Additional randomised controlled trials into early optimisation in these patients with fistulising Crohn's disease is warranted in the setting of a randomised controlled trial are needed. The challenge when using therapeutic drug monitoring with infliximab (and with biologics in general) is the heterogeneity of the assays we have available and the lack of knowledge looking into optimal target levels. Previous studies have proposed several different "optimal" cut-off levels. 6-8, 16, 17 This variability is explained by multiple factors. First, different assays have been used and they are not necessarily equivalent making extrapolation difficult. Second, optimal timing for testing has not been established and has been variable (after 4 weeks of the dose vs. trough levels). Third, the outcomes of these studies have been diverse (mucosal healing, clinical remission, and normal CRP levels). Most importantly, it is likely that "one size does not fit all" and different patients with specific phenotypes need different target goals, especially since serum and tissue drug levels do not always correlate. 18 It is important to mention that we found that the patients with infliximab level in the highest quartile did achieve a higher rate of fistula healing, this was not seen with fistula closure. The exact explanation for this phenomenon is not clear. This may be due to the fact that some fistulas do not have active inflammation and consist of a fibrotic tract. Another interesting finding was that women had a lower rate of fistula closure. It is unclear what the mechanism of this finding is as there was no difference in infliximab levels between genders. A population based study of Crohn's disease patients showed an overall 20% higher rate of development of fistulas in women but there was no reported information on differences in therapy response rates. 1 Interestingly, in the study by Present et al., the benefit of infliximab in fistulising Crohn's disease is numerically higher in men than women (74% of men and 54% of women achieved the primary outcome), even though the authors report the benefit of infliximab over placebo was significantly higher in both genders after adjusting for other variables. 4 Further research into response to therapy of fistulising Crohn's disease by gender is warranted. This study has several limitations. First, while clinical data were prospectively collected, perianal exams were not performed for the purpose of this study and collected retrospectively, even though the exam is systematically documented in the participating clinical sites. In order to overcome this limitation, only patients who had documented perianal exams in the endoscopy reports were included. Photographic documentation was available in 98 out of 117 patients (84%). Moreover, the fact that patients had infliximab levels measured as standard of care introduces bias as it is likely that those patients that had levels checked had partial or nonresponse. Nevertheless, the investigators at both study sites commonly check levels "pro-actively" and not only in cases of lack or loss of response. Another important issue to consider is that we do not have information on the type of fistula (e.g. simple vs. complex). Different type of fistulas may require different "optimal" dose regiments.
In conclusion, this study suggests that infliximab levels are associated fistula healing/closure and levels higher than what has been described for mucosal healing may be needed in order to achieve therapeutic success in penetrating Crohn's disease. Randomised controlled trials comparing target infliximab levels for mucosal healing, fistula healing and closure are warranted.
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